Upgrade to SI Premium - Free Trial

ResMed (RMD) PT Lowered to $180 at Wolfe Research

May 1, 2026 5:32 AM
Wolfe Research analyst Mike Polark lowered the price target on ResMed (NYSE: RMD) to $180.00 (from $230.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change